Micafungine Viatris (Micafungin)

Micafungine is an echinocandin antifungal used to treat systemic and mucosal Candida infections.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves esophageal lesions caused by Candida species.
• Candida peritonitis: controls intra‑abdominal Candida infection.
• Febrile neutropenia: provides empirical antifungal coverage in neutropenic patients at risk of invasive fungal disease.

• Micafungin inhibits the enzyme β‑1,3‑D‑glucan synthase, which is essential for synthesizing 1,3‑β‑D‑glucan, a critical component of the fungal cell wall. Disruption of glucan synthesis weakens the cell wall, leading to osmotic instability and fungal cell lysis without affecting human cells.

Micafungine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient temperature elevation during infusion.
• Headache: mild to moderate headache reported.
• Nausea: occasional gastrointestinal upset.
• Infusion‑related reactions: flushing, chills, or rigors.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring monitoring.
• Anaphylaxis: acute hypersensitivity reaction.
• Severe hypotension: marked blood pressure drop during infusion.
• Renal impairment: acute kidney injury in susceptible patients.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Fatal outcomes: extremely rare but reported in critically ill patients.

When using Micafungine, clinicians should observe several safety measures.

• Renal function: assess baseline renal status and monitor during therapy.
• Hepatic function: check liver enzymes before and periodically during treatment.
• Drug interactions: review concomitant medications for potential CYP interactions.
• Pregnancy: prescribe only if potential benefit justifies potential risk to the fetus.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine can interact with other drugs, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure.
• Co‑administration with other echinocandins: increased risk of toxicity.
• Concurrent use with potent CYP3A4 inhibitors (e.g., ketoconazole): may elevate micafungin levels.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may increase micafungin concentrations.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustments.
• Statins (e.g., simvastatin): monitor for myopathy or rhabdomyysis.